



Multiple Sclerosis, Complications and Therapeutics 2.0

Guest Editors:

Prof. Dr. Vasso Apostolopoulos

Institute for Health and Sport,
Victoria University, Melbourne,
VIC 3011, Australia

Dr. Narges Dargahi

Institute for Health and Sport,
Victoria University, Melbourne,
VIC 3000, Australia

Dr. Jack Feehan

Institute for Health and Sport,
Victoria University, Melbourne,
VIC 3030, Australia

Deadline for manuscript
submissions:

closed (30 October 2021)

Message from the Guest Editors

For improved MS treatments it is relatively weak as compared to other CNS disorders, although there are a number of different drug classes in development including;

- Monoclonal Antibodies - to block destructive immune cells entering brain and spinal cord
- Immunosuppressant's - suppress immune system and prevent myelin damage
- Potassium channel blockers - improve the conduction of demyelinated fibers
- Protein growth factors - to limit demyelination and oligodendrocyte injury
- Immunotherapy / Vaccines - to switch immune response to protect neurons and prevent demyelination

This special issue is now open and is seeking research papers and reviews on MS therapeutics from animal models to human clinical studies, and MS complications and side effects of certain therapeutics.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com